Oropharyngeal Squamous Cell Carcinoma Clinical Trial
Official title:
A Pilot Study to Evaluate the Utility of Interim Digital PET/CT in Predicting Outcomes for Locally Advanced Oropharyngeal Cancer
This pilot trial studies how well interim digital positron emission tomography (PET)/computed tomography (CT) works in predicting outcomes in participants with oropharyngeal cancer that has spread from its original site of growth to nearby tissues or lymph nodes who are undergoing chemoradiation therapy. Diagnostic procedures, such as PET/CT may help measure a participant's response to treatment.
PRIMARY OBJECTIVES:
I. To evaluate the utility of early (i.e. during treatment) digital (d)PET as a diagnostic
tool to predict local control 6 months after definitive chemoradiation for patients with
locally advanced oropharyngeal carcinoma.
SECONDARY OBJECTIVES:
I. To study the association between dynamic dPET parameters taken at early time points (i.e.
during treatment) and complete response (CR) on PET after definitive chemoradiation.
II. To study the association between dynamic dPET parameters taken at early time points (i.e.
during) treatment and 2 year LC after definitive chemoradiation.
III. To assess the ability of dynamic dPET compared to conventional PET or
conventional-equivalent dPET reconstruction to identify tumor volumes with greater
sensitivity at the time of before (dPET1), during (dPET2, dPET3) and after (dPET4, dPET5)
chemoradiation.
OUTLINE:
Participants receive radiotracer injection and undergo dPET/CT over 20-75 minutes at
baseline, during the 2nd and 4th week of radiotherapy, and 3 months after the completion of
chemoradiation therapy.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06174428 -
Validity of Viome's Oral/Throat Cancer Test
|
||
| Recruiting |
NCT05098119 -
Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002)
|
Phase 2 | |
| Suspended |
NCT03952585 -
De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
|
Phase 2/Phase 3 | |
| Terminated |
NCT03618134 -
Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03421470 -
Docetaxel and Radiation Therapy in Treating Patients With HPV Positive Oropharynx Cancer
|
Phase 3 | |
| Completed |
NCT06314711 -
Ex Vivo 3D-ultrasound for Oropharyngeal Cancer
|
N/A | |
| Completed |
NCT04572100 -
Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT06055868 -
People Living With HIV, Oral and Oropharyngeal Cancer, and Health Equity
|
||
| Recruiting |
NCT05522881 -
The Registry Study of Genetic Alterations of Oropharyngeal Cancer in Taiwan
|
||
| Recruiting |
NCT04222543 -
Imaging of Tumour Microenvironment in Patients With Oropharyngeal Head and Neck Squamous Cell Carcinoma Using RGD PET/CT Imaging
|
Phase 2 | |
| Recruiting |
NCT04564989 -
Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC
|
||
| Active, not recruiting |
NCT04965792 -
Post-treatment Surveillance in HPV+ Oropharyngeal SCC
|
||
| Recruiting |
NCT06356272 -
Oropharynx (OPX) Biomarker Trial
|
||
| Active, not recruiting |
NCT01874171 -
Determination of Cetuximab Versus Cisplatin Early and Late Toxicity Events in HPV+ OPSCC
|
Phase 3 | |
| Recruiting |
NCT05333523 -
Personalized Elective Neck Irradiation Guided by Sentinel Lymph Node Biopsy in Larynx and Pharynx Cancer. The PRIMO Study.
|
Phase 3 | |
| Completed |
NCT03618654 -
Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma
|
Early Phase 1 | |
| Recruiting |
NCT04801472 -
Optimisation of Potential Dental Implant Sites Protection for Rehabilitation in Patients With Head and Neck Cancer: Impact of Virtual Implants Visualisation on Dosimetry (OPPIDOM)
|
N/A | |
| Active, not recruiting |
NCT03410615 -
Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC
|
Phase 2 | |
| Recruiting |
NCT05268614 -
Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma
|
Phase 2 | |
| Not yet recruiting |
NCT05582590 -
Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal Cancers
|
Phase 1 |